Hasan, W.N.W., Chin, K.Y., Jolly, J.J., et al. (2018) Identifying Potential Therapeutics for Osteoporosis by Exploiting the Relationship between Mevalonate Pathway and Bone Metabolism. Endocrine, Metabolic and Immune Disorders—Drug Targets, 18, 450-457.
https://doi.org/10.2174/1871530318666180423122409

has been cited by the following article:

• TITLE: Postmenopausal Osteoporosis and Osteopenia Management with a Combination of Once-Monthly Oral Ibandronate and Cholecalciferol—A Systematic Review

  AUTHORS: Mauro Geller, Mendel Suchmacher, Marcio Cohen, Spyros G. E. Mezitis, Flavia Wajnsztajn-Theil, Karin G. Cunha, Rafael Nigri

  KEYWORDS: Ibandronate, Cholecalciferol, Postmenopausal Osteoporosis, Postmenopausal Osteopenia, Systematic Review

  JOURNAL NAME: International Journal of Clinical Medicine, Vol.14 No.1, January 31, 2023

  ABSTRACT: Postmenopausal osteoporosis and osteopenia are chronic and uncurable conditions that invariably lead to an increased risk of vertebral, hip, and femoral neck fracture if left untreated. Clinical guidelines establish, in general, pharmacological combinations allied to lifestyle changes as the mainstay of their management, and also increasing bone marrow density, lowering fracture risk, and improving quality of life are their main therapeutic goals. The objective of this systematic review was to analyze the available data in the scientific medical literature regarding the role of the ibandronate and cholecalciferol combination in postmenopausal osteoporosis and osteopenia management. Based on our results, we concluded that the above combination is safe and feasible for the clinical control of both conditions.